Opinion

Video

Mitigating Toxicities of Dato-DXd, Sacituzumab Govitecan, and HER3-DXd

Author(s):

Mark A. Socinski, MDHelena A. Yu, MD

Benjamin Levy, MD, compares the common toxicities associated with datopotamab deruxtecan (Dato-DXd), sacituzumab govitecan, and patritumab deruxtecan (HER3-DXd), and shares practical tips for managing these toxicities in the clinical setting to optimize patient care and minimize adverse effects.

  1. How do the toxicities of Dato-DXd, sacituzumabgovitecan and HER3-DXd compare? How are you managing these in your clinical practice?
    • Hayashi et al. ELCC 2024. HER3-DXd in previously treated patients with advanced EGFR mutated NSCLC: Updated safety results from HERTHENA-Lung01
    • Sands et al. ASCO 2024. Analysis of drug-related interstitial lung disease (ILD) inpatients (pts) treated with datopotamab deruxtecan (Dato-DXd).
Related Videos
T. Jeroen N. Hiltermann, MD, of University of Groningen
Hope Rugo, MD, FASCO, and Aditya Bardia, MD, MPH, FASCO
Benjamin Besse, MD, PhD, of Institute Gustave Roussy
Hope Rugo, MD, FASCO, and Aditya Bardia, MD, MPH, FASCO
Xiuning Le, MD, PhD, of The University of Texas MD Anderson Cancer Center
Natasha B. Leighl, MD, BSc, MMSc, of the Princess Margaret Cancer Centre
John V. Heymach, MD, PhD, chair, Thoracic/Head and Neck Medical Oncology, and the David Bruton Endowed Chair in Cancer Research, The University of Texas MD Anderson Cancer Center
Yi-Long Wu, MD, PhD, of the Guangdong Lung Cancer Institute, Guangdong Provincial People’s Hospital (Guangdong Academy of Medical Sciences), Southern Medical University
Related Content
FDA
September 12th 2024

FDA Approves Subcutaneous Atezolizumab and Hyaluronidase-tqjs for Use in All Indications of IV Atezolizumab

OncLive On Air
September 11th 2024

Oncology Experts Preview Top Abstracts From the 2024 ESMO Congress

Danny Nguyen, MD
September 11th 2024

Amivantamab Plus Lazertinib Delays Symptomatic Progression in EGFR+ Advanced NSCLC

Narjust Florez, MD
September 5th 2024

Florez Focuses on Patient-Centered NSCLC Biomarker Testing Discussions

Luis Raez, MD, of Memorial Cancer Institute
September 11th 2024

Timing of Immunotherapy Administration Is a Key Question to be Answered in Lung Cancer

Benjamin Besse, MD, PhD, a medical oncologist and professor of medicine at Paris Saclay University, Institut Gustave Roussy, Villejuif, France
September 11th 2024

Tusamitamab Ravtansine Misses Survival End Points in Advanced NSCLC Trial